EZH2 and small cell lung carcinoma: In addition to the ANPY classification, this study proposes another approach to stratify SCLC patients based on CRACD status, providing a potential predictive molecular signature for the effectiveness of T cell-based ICB therapies combined with EZH2 inhibitors.